[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-respiratory-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-respiratory-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,85,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100623422","effectiveness-and-implementation-of-a-national-guideline-for-acute-respiratory-tract-infections-to-reduce-antibiotic-prescribing-in-swiss-primary-care-100623422",false,"NCT07396428","Effectiveness and Implementation of a National Guideline for Acute Respiratory Tract Infections to Reduce Antibiotic Prescribing in Swiss Primary Care","Effectiveness and Implementation of a National Guideline for Acute Respiratory Tract Infections to Reduce Antibiotic Prescribing in Swiss Primary Care: the ImpProGUIDE Hybrid Type II Effectiveness-implementation Trial","ImpProGUIDE","Inclusion criteria for quality circles (QCs)\n\n* Willing to participate in a study mainly conducted in French\n* Agreeing to participate in evaluation surveys\n\nExclusion criteria for QCs\\*\n\n\\- Not having any physician included in the study\n\nInclusion criteria for walk-in clinics\n\n* The clinic offers general practice\u002Fprimary care medicine consultations, including emergencies\n* The clinic includes at least five physicians\n* The clinic has an \"Admission to practice charged to Swiss compulsory health insurance\"\n* The clinic plans to still be active in April 2026\n* Located in one of the following cantons: Vaud, Geneva, Valais, Fribourg, Jura, Neuchatel, Bern, Ticino.\n* Serving mainly adult patients\n* Willing to participate in the study\n\nPhysicians in QCs fulfilling all of the following inclusion criteria are eligible for the study:\n\n* Registered primary care physicians\n* Specialist title in general internal medicine or practicing physician.\n* Practicing in one of the following cantons: Vaud, Geneva, Valais, Fribourg, Jura, Neuchatel, Bern, Ticino.\n* Participating in a QC or working in an outpatient clinic participating in the study\\*.\n* Willing to participate in a study mainly conducted in French.\n* Agreeing to participate in evaluation surveys and agreeing to be invited to interviews\n\nEligibility criteria for physicians in clinics :\n\n\\- Having a clinical activity as primary care physician or supervising clinical activity of physicians in post-graduate training within a clinic included in the study\n\nThe only exclusion criterion for physicians is planning to retire before April 2026.\n\n\\*Note: not all physicians from a QC or a clinic are expected or required to participate individually in the study, but at least one should participate.","ALL",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The ImpProGUIDE study aims to find out whether implementing new Swiss national guidelines for acute respiratory infections (ARI) can help to reduce antibiotic prescribing in primary care. In Switzerland, most antibiotics are prescribed in outpatient care, and many of these prescriptions may not be needed - especially when infections are caused by viruses, which antibiotics do not treat. Reducing overuse of antibiotics is important to slow the spread of antibiotic resistance.\n\nThe new guidelines were developed by the Swiss Society for Infectious Diseases (SSI) to support family doctors in managing ARIs, based on a syndromic approach. They recommend the targeted use of point-of-care C-reactive protein (CRP) testing when bacterial infection is suspected, as well as shared decision-making with patients.\n\nThis study will be carried out in quality circles (QCs) - small groups of family doctors who meet regularly to discuss and improve clinical practice - and in walk-in clinics in French- and Italian-speaking regions of Switzerland. Each will be randomly assigned to either an \"intervention\" group or a \"control\" group.\n\nIn the intervention group, QC moderators and medical center directors will receive implementation resources to lead a session and distribute materials to their group in autumn 2025 on the new guidelines. Doctors can then decide whether or not to use the recommendations in their consultations.\n\nIn the control group, QCs and centers will continue their regular activities. They will receive access to the same educational materials later, in summer 2026.\n\nThroughout the study, the researchers will collect de-identified data from health insurance billing records to track antibiotic prescribing and the use of diagnostic tests. Doctors and QC moderators will also be invited to complete short online surveys twice a year (10-15 minutes) and may be asked to join optional interviews or group discussions after the winter season.\n\nThe study will also explore the effectiveness of the implementation strategies on the adoption of the SSI guidelines, as well as the barriers and facilitators to adoption. This study type is known as a hybrid effectiveness implementation study, simultaneously evaluating an intervention's impact on antibiotic prescribing and the strategies used to implement the new national guidelines in a real-world setting.\n\nParticipation in the study is voluntary. Doctors can withdraw at any time. All data will be handled confidentially and in line with Swiss data protection laws.\n\nThe study is funded by the Swiss National Science Foundation. No support is received from pharmaceutical companies or manufacturers of diagnostic tests.",[26,27],"Acute Respiratory Infection","Influenza-like Illness",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"family medicine","primary care","implementation","hybrid design","effectiveness-implementation study","general medicine","outpatient","antibiotics","antibiotic prescribing","antimicrobial resistance","antimicrobial stewardship","guidelines","shared decision making","CRP","c-reactive protein","RECRUITING","2026-06-18",{"date":47,"type":48},"2026-06-24","ACTUAL",{"date":50,"type":48},"2025-05-19",{"date":52,"type":20},"2026-11",{"name":54,"class":55},"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100501821","pos-ari-er-observational-study-of-acute-respiratory-infections-100501821","NCT05814237","POS-ARI-ER Observational Study of Acute Respiratory Infections","Perpetual Observational Study of Acute Respiratory Infections Presenting Via Emergency Rooms and Other Acute Hospital Care Settings","POS-ARI-ER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical suspicion of a new episode of acute respiratory tract infection, with onset in the last 10 days\n* Patient presents to an emergency room or secondary care setting\n* Informed consent is provided by patient or their legal representative\n\nExclusion Criteria:\n\n* Patient has been transferred from another hospital\n* Patient admitted to hospital for \\>2 days at the time of enrolment\n* Patient has been previously enrolled in the POS-ARI-ER study","18 Years",{"count":67,"type":20},11750,"OBSERVATIONAL","Acute respiratory infections (ARI) are one of the most frequent reasons for hospital admission and antibiotic use, and can be caused by a broad range of pathogens, including respiratory viruses with proven epidemic potential, e.g. influenza and coronaviruses. The POS-ARI-ER study will focus on describing the different routine diagnostic and therapeutic practices in the work-up and treatment of ARI, as well as clinical outcomes across the patient population. In addition, POS-ARI-ER aims to characterise both the adult patient population with ARI presenting to acute hospital settings in Europe, and the aetiology of ARI in these patients.",[26,71],"Acute Respiratory Tract Infection",[73,74],"Infections","Communicable Diseases","2024-09-02",{"date":77,"type":48},"2024-09-19",{"date":79,"type":48},"2023-06-20",{"date":81,"type":20},"2026-02-28",{"name":83,"class":55},"European Clinical Research Alliance for Infectious Diseases (ECRAID)",23,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":56},"100370110","signature-of-the-host-response-to-a-respiratory-viral-infection-in-the-prediction-of-bronchiolitis-obliterans-100370110","NCT04099082","Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans","ALLOPIV","Inclusion Criteria :\n\n* Adults having received a hematopoietic stem cell transplantation for less than two years\n* Availability of respiratory function tests prior to infection\n* Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and\u002For lower respiratory tract\n* Symptoms of respiratory infection ≤ 5 days\n* Signed informed consent\n\nExclusion Criteria:\n\n* Presence of a respiratory virus infection other than PIV\n* Viral respiratory co-infections\n* Bacterial or fungal respiratory infections\n* Treatment with ribavirin, oseltamivir or any other antiviral with activity against respiratory viruses\n* Patient not affiliated or beneficiary of a social security system\n* Patient deprived of liberty or protected\n* Pregnant or breastfeeding woman",{"count":93,"type":20},14,"Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (PIV), respiratory syncytial virus, metapneumovirus). It is likely that the alloimmune response triggered by the respiratory virus is inadequate and leads to the peribronchiolar fibrotic process. The objective is to analyze the kinetics of profiles of the blood and respiratory host responses resulting from a high or low parainfluenza respiratory infection, in order to evaluate if the occurrence of a BO is associated with a specific signature We will evaluate the predictive signature of a BO after a parainfluenza virus infection by characterizing the differences between the patients evolving and those not evolving to a BO at 2 months after the infection.",[96,26,97],"Allogeneic Hematopoietic Stem Cell Recipients","Parainfluenza Virus (PIV)","2024-07-15",{"date":100,"type":48},"2024-07-17",{"date":102,"type":48},"2021-03-01",{"date":104,"type":20},"2025-03-01",{"name":106,"class":55},"Assistance Publique - Hôpitaux de Paris",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100508613","isotonic-saline-for-children-with-bronchiolitis-100508613","NCT05902702","Isotonic Saline for Children With Bronchiolitis","Isotonic Saline for Children With Bronchiolitis - a Randomized Controlled Non-inferiority Trial","Inclusion Criteria:\n\n* Children aged 0-12 months, whose parents give informed consent to participate, with symptoms of bronchiolitis including at least one of:\n\n  * Runny nose\n  * Dry and persistent cough\n  * Labored breathing (tachypnea, retractions, nasal flaring)\n  * Grunting\n  * Cyanosis or apnea\n  * Wheezing or crackles on auscultation\n  * O2 saturations below 92 %\n  * Difficulties feeding\n\nExclusion Criteria:\n\n* Children with cystic fibrosis or other serious congenital lung diseases\n* Children in whom treatment with short-acting beta-2 agonist is initiated (as this is delivered in nebulized isotonic saline).","1 Day","12 Months",{"count":117,"type":20},300,[23],"The goal of this randomized clinical trial is to investigate the optimal supportive treatment of bronchiolitis in infants from 0-12 months of age. The main question\\[s\\] it aims to answer are:\n\n* To investigate whether isotonic saline should be used as supportive treatment for children with bronchiolitis, and if so, identify the optimal route of administration. The primary outcome is duration of hospitalization.\n* To investigate the current epidemiology of the viral pathogens causing bronchitis in children in Denmark, and to assess whether children infected with specific pathogens might benefit from treatment with isotonic saline.\n\nThe children are randomized after inclusion through computer randomization to one of the 3 arms in the study:\n\n1. Nebulized isotonic saline\n2. Nasal irrigation with isotonic saline\n3. No treatment with saline\n\nThe investigators will compare treatment with saline (both methods) with no treatment, and the investigators will also compare the two methods of delivery of saline (nebulized vs. nasal irrigation).",[121,122,123,124,26],"Bronchiolitis","Respiratory Disease","Asthma in Children","Viral Infection",[126,127,128,129],"Nebulized saline","Nasal saline drops","Nasal saline irrigation","Respiratory severity score","NOT_YET_RECRUITING","2023-06-13",{"date":133,"type":48},"2023-06-15",{"date":135,"type":20},"2023-09",{"date":137,"type":20},"2029-09",{"name":139,"class":55},"Slagelse Hospital"]